Vanguard Capital Management
CVKD icon

Vanguard Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Vanguard Capital Management’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
50,137
+4,936
+11% +$23.4K ﹤0.01% 3834
2026
Q1 		$231K Buy
+45,201
New +$317K ﹤0.01% 3781

Other funds holding CVKD

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

Vanguard Capital Management's CVKD Position: Q2 2026 in Review

Vanguard Capital Management increased its Cadrenal Therapeutics (CVKD) stake by 11% in Q2 2026, buying an estimated $23.4K and bringing the position to 50,137 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Vanguard Capital Management first reported a position in CVKD in Q1 2026 and has held it in 2 quarters since. The position peaked at $231K in Q1 2026. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Vanguard Capital Management held 50,137 shares of Cadrenal Therapeutics worth $167K as of Q2 2026.
  • Vanguard Capital Management bought 4,936 Cadrenal Therapeutics shares in Q2 2026, an estimated $23.4K.
  • Cadrenal Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3834 holding.
  • Vanguard Capital Management first reported a position in Cadrenal Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Cadrenal Therapeutics position peaked at $231K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.